Cite
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
MLA
Marston, Nicholas A., et al. “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.” Circulation, vol. 141, no. 20, May 2020, pp. 1600–07. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.120.046397.
APA
Marston, N. A., Gurmu, Y., Melloni, G. E. M., Bonaca, M., Gencer, B., Sever, P. S., Pedersen, T. R., Keech, A. C., Roselli, C., Lubitz, S. A., Ellinor, P. T., O’Donoghue, M. L., Giugliano, R. P., Ruff, C. T., & Sabatine, M. S. (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 141(20), 1600–1607. https://doi.org/10.1161/CIRCULATIONAHA.120.046397
Chicago
Marston, Nicholas A, Yared Gurmu, Giorgio E M Melloni, Marc Bonaca, Baris Gencer, Peter S Sever, Terje R Pedersen, et al. 2020. “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.” Circulation 141 (20): 1600–1607. doi:10.1161/CIRCULATIONAHA.120.046397.